43692 Federal Register / Vol. 83, No. 166 / Monday, August 27, 2018 / Notices 

ANNUAL BURDEN ESTIMATES

Instrument Number of 

respondents 

Number of 

responses per 

respondent 

Average 

burden hours 

per response 

Total burden 

hours 

ADR ................................................................................................................. 275 1 1 275

Estimated Total Annual Burden 

Hours: 275. 

Additional Information: Copies of the 

proposed collection may be obtained by 

writing to the Administration for 

Children and Families, Office of 

Planning, Research and Evaluation, 330 

C Street SW, Washington, DC 20201. 

Attention Reports Clearance Officer. All 

requests should be identified by the title 

of the information collection. Email 

address: infocollection@acf.hhs.gov. 

OMB Comment: OMB is required to 

make a decision concerning the 

collection of information between 30 

and 60 days after publication of this 

document in the Federal Register. 

Therefore, a comment is best assured of 

having its full effect if OMB receives it 

within 30 days of publication. Written 

comments and recommendations for the 

proposed information collection should 

be sent directly to the following: Office 

of Management and Budget, Paperwork 

Reduction Project, Email: OIRA_

SUBMISSION@OMB.EOP.GOV; Attn: 

Desk Officer for the Administration for 

Children and Families. 

Robert A. Sargis, 

Reports Clearance Officer. 

[FR Doc. 2018–18495 Filed 8–24–18; 8:45 am] 

BILLING CODE 4184–34–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

Meeting of the Presidential Advisory 

Council on Combating AntibioticResistant Bacteria 

AGENCY: Department of Health and 

Human Services, Office of the Secretary, 

Office of the Assistant Secretary for 

Health. 

ACTION: Notice. 

SUMMARY: As stipulated by the Federal 

Advisory Committee Act, the 

Department of Health and Human 

Services (HHS) is hereby giving notice 

that a meeting is scheduled to be held 

for the Presidential Advisory Council on 

Combating Antibiotic-Resistant Bacteria 

(Advisory Council). The meeting will be 

open to the public; a public comment 

session will be held during the meeting. 

Pre-registration is required for members 

of the public who wish to attend the 

meeting and who wish to participate in 

the public comment session. Individuals 

who wish to attend the meeting and/or 

send in their public comment via email 

should send an email to CARB@hhs.gov. 

Registration information is available on 

the website http://www.hhs.gov/ash/ 

carb/ and must be completed by 

September 19, 2018; all in-person 

attendees must pre-register by this date. 

Additional information about registering 

for the meeting and providing public 

comment can be obtained at http://

www.hhs.gov/ash/carb/ on the Meetings 

page. 

DATES: The meeting is scheduled to be 

held on September 26, 2018, from 9:00 

a.m. to 5:00 p.m. ET (times are tentative 

and subject to change). The confirmed 

times and agenda items for the meeting 

will be posted on the website for the 

Advisory Council at http://

www.hhs.gov/ash/carb/ when this 

information becomes available. Preregistration for attending the meeting in 

person is required to be completed no 

later than September 19, 2018; public 

attendance at the meeting is limited to 

the available space. 

ADDRESSES: This public meeting is being 

held at the Sheraton Columbus Hotel at 

Capitol Square, 75 East State Street, 

Columbus, OH, 43215. The meeting can 

also be accessed through a live webcast 

on the day of the meeting. For more 

information, visit http://www.hhs.gov/ 

ash/carb/. 

FOR FURTHER INFORMATION CONTACT: 

Jomana Musmar, Acting Designated 

Federal Officer, Presidential Advisory 

Council on Combating AntibioticResistant Bacteria, Office of the 

Assistant Secretary for Health, U.S. 

Department of Health and Human 

Services, Room 715H, Hubert H. 

Humphrey Building, 200 Independence 

Avenue SW, Washington, DC 20201. 

Phone: (202) 690–5566; email: CARB@

hhs.gov. 

SUPPLEMENTARY INFORMATION: Under 

Executive Order 13676, dated 

September 18, 2014, authority was given 

to the Secretary of HHS to establish the 

Advisory Council, in consultation with 

the Secretaries of Defense and 

Agriculture. Activities of the Advisory 

Council are governed by the provisions 

of Public Law 92–463, as amended (5 

U.S.C. App.), which sets forth standards 

for the formation and use of federal 

advisory committees. 

The Advisory Council will provide 

advice, information, and 

recommendations to the Secretary of 

HHS regarding programs and policies 

intended to support and evaluate the 

implementation of Executive Order 

13676, including the National Strategy 

for Combating Antibiotic-Resistant 

Bacteria and the National Action Plan 

for Combating Antibiotic-Resistant 

Bacteria. The Advisory Council shall 

function solely for advisory purposes. 

In carrying out its mission, the 

Advisory Council will provide advice, 

information, and recommendations to 

the Secretary regarding programs and 

policies intended to preserve the 

effectiveness of antibiotics by 

optimizing their use; advance research 

to develop improved methods for 

combating antibiotic resistance and 

conducting antibiotic stewardship; 

strengthen surveillance of antibioticresistant bacterial infections; prevent 

the transmission of antibiotic-resistant 

bacterial infections; advance the 

development of rapid point-of-care and 

agricultural diagnostics; further research 

on new treatments for bacterial 

infections; develop alternatives to 

antibiotics for agricultural purposes; 

maximize the dissemination of up-todate information on the appropriate and 

proper use of antibiotics to the general 

public and human and animal 

healthcare providers; and improve 

international coordination of efforts to 

combat antibiotic resistance. 

The September 26, 2018, public 

meeting will be dedicated to the 

Advisory Council’s deliberation and 

vote of the Infection Prevention and 

Stewardship Working Group’s draft 

report with recommendations, in 

addition to other topic areas 

surrounding antibiotic-resistance and 

One Health. The meeting agenda will be 

posted on the Advisory Council website 

at http://www.hhs.gov/ash/carb/ when it 

has been finalized. All agenda items are 

tentative and subject to change. 

Public attendance at the meeting is 

limited to the available space. 

Individuals who plan to attend and 

need special assistance, such as sign 

language interpretation or other 

reasonable accommodations, should 

notify the Advisory Council at the 


amozie on DSK3GDR082PROD with NOTICES1
Federal Register / Vol. 83, No. 166 / Monday, August 27, 2018 / Notices 43693 

address/telephone number listed above 

at least one week prior to the meeting. 

For those unable to attend in person, a 

live webcast will be available. More 

information on registration and 

accessing the webcast can be found at 

http://www.hhs.gov/ash/carb/. 

Members of the public will have the 

opportunity to provide comments prior 

to the Advisory Council meeting by 

emailing CARB@hhs.gov. Public 

comments should be sent in by 

midnight September 19, 2018, and 

should be limited to no more than one 

page. All public comments received 

prior to September 19, 2018, will be 

provided to Advisory Council members; 

comments are limited to two minutes 

per speaker. 

Dated: August 21, 2018. 

Jomana F. Musmar, 

Acting Designated Federal Officer, 

Presidential Advisory Council on Combating 

Antibiotic-Resistant Bacteria Committee 

Manager. 

[FR Doc. 2018–18483 Filed 8–24–18; 8:45 am] 

BILLING CODE 4150–44–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

National Cancer Institute; Notice of 

Closed Meetings 

Pursuant to section 10(d) of the 

Federal Advisory Committee Act, as 

amended, notice is hereby given of the 

following meetings. 

The meetings will be closed to the 

public in accordance with the 

provisions set forth in sections 

552b(c)(4) and 552b(c)(6), Title 5 U.S.C., 

as amended. The grant applications and 

the discussions could disclose 

confidential trade secrets or commercial 

property such as patentable material, 

and personal information concerning 

individuals associated with grant 

applications, the disclosure of which 

would constitute a clearly unwarranted 

invasion of personal privacy. 

Name of Committee: National Cancer 

Institute Special Emphasis Panel; NCI SPORE 

III. 

Date: September 19–20, 2018. 

Time: 5:00 p.m. to 5:00 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: Gaithersburg Marriott 

Washingtonian Center, 9751 Washingtonian 

Boulevard, Gaithersburg, MD 20878. 

Contact Person: Wlodek Lopaczynski, 

M.D., Ph.D., Scientific Review Officer, 

Research Programs Review Branch, Division 

of Extramural Activities, National Cancer 

Institute, NIH, 9609 Medical Center Drive, 

Room 7W514, Bethesda, MD 20892–9750, 

240–276–6340, lopacw@mail.nih.gov. 

Name of Committee: National Cancer 

Institute Special Emphasis Panel; SEP 4 for 

Provocative Questions. 

Date: September 21, 2018. 

Time: 7:30 a.m. to 6:00 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: Bethesda North Marriott Hotel & 

Conference Center, 5701 Marinelli Road, 

North Bethesda, MD 20852. 

Contact Person: Clifford W. Schweinfest, 

Ph.D., Scientific Review Officer, Special 

Review Branch, Division of Extramural 

Activities, National Cancer Institute, NIH, 

9609 Medical Center Drive, Room 7W108, 

Bethesda, MD 20892–9750, 240–276–6343, 

schweinfestcw@mail.nih.gov. 

Name of Committee: National Cancer 

Institute Special Emphasis Panel; SEP–1 for 

Provocative Questions. 

Date: October 4, 2018. 

Time: 7:30 a.m. to 4:00 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: Cambria Hotel Rockville, 1 Helen 

Heneghan Way, Rockville, MD 20850. 

Contact Person: Hasan Siddiqui, Ph.D., 

Scientific Review Officer, Special Review 

Branch, Division of Extramural Activities, 

National Cancer Institute, NIH, 9609 Medical 

Center Drive, Room 7W240, Bethesda, MD 

20892–9750, 240–276–5122, hasan.siddiqui@

nih.gov. 

Name of Committee: National Cancer 

Institute Special Emphasis Panel; SEP–3 for 

Provocative Questions. 

Date: October 9, 2018. 

Time: 8:00 a.m. to 6:00 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: Bethesda North Marriott Hotel & 

Conference Center, 5701 Marinelli Road, 

North Bethesda, MD 20852. 

Contact Person: Adriana Stoica, Ph.D., 

Scientific Review Officer, Resources and 

Training Review Branch, Division of 

Extramural Activities, National Cancer 

Institute, NIH, 9609 Medical Center Drive, 

Room 7W234, Bethesda, MD 20892–9750, 

240–276–6368, Stoicaa2@mail.nih.gov. 

Name of Committee: National Cancer 

Institute Special Emphasis Panel; Traceback 

Testing: Identification and Genetic 

Counseling of Mutation Carriers (U01). 

Date: October 10, 2018. 

Time: 11:00 a.m. to 1:00 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: National Cancer Institute, Shady 

Grove, 9609 Medical Center Drive, Room 

7W248, Rockville, MD 20850 (Telephone 

Conference Call). 

Contact Person: Anita T. Tandle, Ph.D., 

Scientific Review Officer, Research Programs 

Review Branch, Division of Extramural 

Activities, National Cancer Institute, NIH, 

9609 Medical Center Drive, Room 7W248, 

Bethesda, MD 20892–9750, 240–276–5007, 

tandlea@mail.nih.gov. 

Name of Committee: National Cancer 

Institute Special Emphasis Panel; SEP–5 for 

Provocative Questions. 

Date: October 18–19, 2018. 

Time: 6:00 p.m. to 5:00 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: Bethesda Marriott Suites, 6711 

Democracy Boulevard, Bethesda, MD 20817. 

Contact Person: Byeong-Chel Lee, Ph.D., 

Scientific Review Officer, Resources and 

Training Review Branch, Division of 

Extramural Activities, National Cancer 

Institute, NIH, 9609 Medical Center Drive, 

Room 7W238, Bethesda, MD 20892–9750, 

240–276–7755, byeong-chel.lee@nih.gov. 

Name of Committee: National Cancer 

Institute Special Emphasis Panel; SEP–1 NCI 

Clinical and Translational R21 and Omnibus 

R03. 

Date: October 25, 2018. 

Time: 10:00 a.m. to 5:00 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: National Cancer Institute, Shady 

Grove, 9609 Medical Center Drive, Room 

7W242, Rockville, MD 20850 (Telephone 

Conference Call). 

Contact Person: Zhiqiang Zou, M.D., Ph.D., 

Scientific Review Officer, Special Review 

Branch, Division of Extramural Activities, 

National Cancer Institute, NIH, 9609 Medical 

Center Drive, Room 7W242, Bethesda, MD 

20892–9750, 240–276–6372, zouzhiq@

mail.nih.gov. 

Name of Committee: National Cancer 

Institute Special Emphasis Panel; NCI U01 

Review: Integrating Biospecimens into 

Clinical Assay Development. 

Date: November 15, 2018. 

Time: 12:00 p.m. to 2:00 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: National Cancer Institute, Shady 

Grove, 9609 Medical Center Drive, Room 

7W116, Rockville, MD 20850 (Telephone 

Conference Call). 

Contact Person: Klaus B. Piontek, Ph.D., 

Scientific Review Officer, Research Programs 

Review Branch, Division of Extramural 

Activities, National Cancer Institute, NIH, 

9609 Medical Center Drive, Room 7W116, 

Bethesda, MD 20892–9750, 240–276–7849, 

klaus.piontek@nih.gov. 

(Catalogue of Federal Domestic Assistance 

Program Nos. 93.392, Cancer Construction; 

93.393, Cancer Cause and Prevention 

Research; 93.394, Cancer Detection and 

Diagnosis Research; 93.395, Cancer 

Treatment Research; 93.396, Cancer Biology 

Research; 93.397, Cancer Centers Support; 

93.398, Cancer Research Manpower; 93.399, 

Cancer Control, National Institutes of Health, 

HHS) 

Dated: August 20, 2018. 

Melanie J. Pantoja, 

Program Analyst, Office of Federal Advisory 

Committee Policy. 

[FR Doc. 2018–18399 Filed 8–24–18; 8:45 am] 

BILLING CODE 4140–01–P 


amozie on DSK3GDR082PROD with NOTICES1